<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> is regarded as the most important risk factor for development of oesophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>According to current guidelines, treatment should be limited to symptomatic <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>AIM: To evaluate the expression of Ki67, cyclooxygenase-2 (COX-2) and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> after 12 months of double-dose <z:chebi fb="0" ids="49200">proton pump inhibitor</z:chebi> therapy </plain></SENT>
<SENT sid="3" pm="."><plain>The effectiveness of <z:chebi fb="0" ids="50275">esomeprazole</z:chebi> and <z:chebi fb="0" ids="7915">pantoprazole</z:chebi> was also compared </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: Seventy-seven nondysplastic <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> patients underwent baseline upper endoscopy </plain></SENT>
<SENT sid="5" pm="."><plain>Patients were then randomised into two groups: one group was allocated to receive <z:chebi fb="0" ids="50275">esomeprazole</z:chebi> 40 mg b.d. and the other group <z:chebi fb="0" ids="7915">pantoprazole</z:chebi> 40 mg b.d. for 12 months </plain></SENT>
<SENT sid="6" pm="."><plain>A follow-up endoscopy was performed at the end of treatment </plain></SENT>
<SENT sid="7" pm="."><plain>Sixty-five of 77 patients agreed to undergo oesophageal manometry and 24-h pH-metry </plain></SENT>
<SENT sid="8" pm="."><plain><z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> biopsies, obtained at baseline and after treatment, were analysed using immunohistochemistry to assess Ki67 and COX-2 expression; <z:mpath ids='MPATH_3'>apoptosis</z:mpath> was evaluated using TUNEL </plain></SENT>
<SENT sid="9" pm="."><plain>RESULTS: In the <z:chebi fb="0" ids="50275">esomeprazole</z:chebi> group, a significant decrease in Ki67 and COX-2 expression, as well as an increase in <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, were observed (P &lt; 0.05) </plain></SENT>
<SENT sid="10" pm="."><plain>By contrast, in the <z:chebi fb="0" ids="7915">pantoprazole</z:chebi> group Ki67, COX-2 and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> did not vary significantly from baseline </plain></SENT>
<SENT sid="11" pm="."><plain>By 24-h oesophageal pH-monitoring, a <z:mpath ids='MPATH_458'>normal</z:mpath> acid exposure time was recorded in patients treated with <z:chebi fb="0" ids="50275">esomeprazole</z:chebi>, while those allocated to <z:chebi fb="0" ids="7915">pantoprazole</z:chebi> displayed abnormal acid exposure (P &lt; 0.05) </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: Treatment of <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> patients with high-dose <z:chebi fb="0" ids="50275">esomeprazole</z:chebi>, but not <z:chebi fb="0" ids="7915">pantoprazole</z:chebi>, promoted a decrease in proliferative markers, concomitantly with a decrease in apoptotic cell <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="13" pm="."><plain>Moreover, <z:chebi fb="0" ids="50275">esomeprazole</z:chebi> allowed a better oesophageal acid control than <z:chebi fb="0" ids="7915">pantoprazole</z:chebi> </plain></SENT>
</text></document>